Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.

Tytuł:: Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.
Autorzy:: Seki Y; Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Ichihara A; Department of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Źródło:: PloS one [PLoS One] 2022 Apr 22; Vol. 17 (4), pp. e0267324. Date of Electronic Publication: 2022 Apr 22 (Print Publication: 2022).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:: Human Growth Hormone*
Pituitary Neoplasms*/complications
Pituitary Neoplasms*/diagnosis
Pituitary Neoplasms*/surgery
Adult ; Growth Hormone ; Growth Hormone-Releasing Hormone ; Humans ; Overweight/complications ; Retrospective Studies ; Thyroxine
References:: Lancet. 1990 Aug 4;336(8710):285-8. (PMID: 1973979)
Mediators Inflamm. 2010;2010:434562. (PMID: 20150954)
Endocrine. 2016 Oct;54(1):15-23. (PMID: 27481361)
Endocr J. 2020 Feb 28;67(2):167-175. (PMID: 31776295)
Neuroendocrinology. 2021;111(5):442-450. (PMID: 32335555)
Eur J Endocrinol. 2007 Dec;157(6):695-700. (PMID: 18057375)
Sci Rep. 2019 Nov 7;9(1):16181. (PMID: 31700044)
Ann Endocrinol (Paris). 2015 Jul;76(3):239-47. (PMID: 26072284)
Int J Obes Relat Metab Disord. 1999 Mar;23(3):260-71. (PMID: 10193871)
Eur J Endocrinol. 2010 Jan;162(1):29-35. (PMID: 19773366)
J Clin Endocrinol Metab. 2004 Jul;89(7):3306-12. (PMID: 15240607)
Kidney Int. 2014 Jan;85(1):49-61. (PMID: 24284513)
J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609. (PMID: 21602453)
Endocr J. 2018 Aug 27;65(8):827-832. (PMID: 29910227)
Ann Endocrinol (Paris). 2015 Jul;76(3):191-200. (PMID: 26054868)
Endocr Pract. 2019 Nov;25(11):1191-1232. (PMID: 31760824)
Eur J Endocrinol. 2006 Jul;155(1):61-71. (PMID: 16793951)
Eur J Endocrinol. 2003 Aug;149(2):117-22. (PMID: 12887288)
Neurol Med Chir (Tokyo). 2014;54(8):599-605. (PMID: 25070016)
Endocr J. 2013;60(1):97-105. (PMID: 23079545)
Eur J Endocrinol. 2007 Jul;157(1):19-27. (PMID: 17609397)
Pituitary. 2019 Aug;22(4):422-434. (PMID: 31011999)
Endocrinol Metab Clin North Am. 2008 Mar;37(1):151-71, xi. (PMID: 18226735)
Clin Endocrinol (Oxf). 2008 Aug;69(2):292-8. (PMID: 18221393)
J Clin Endocrinol Metab. 1993 Sep;77(3):616-20. (PMID: 8103770)
Am J Kidney Dis. 2009 Jun;53(6):982-92. (PMID: 19339088)
Endocr J. 2012;59(9):771-80. (PMID: 22673406)
J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921. (PMID: 27736313)
Substance Nomenclature:: 12629-01-5 (Human Growth Hormone)
9002-72-6 (Growth Hormone)
9034-39-3 (Growth Hormone-Releasing Hormone)
Q51BO43MG4 (Thyroxine)
Entry Date(s):: Date Created: 20220422 Date Completed: 20220426 Latest Revision: 20220622
Update Code:: 20240104
PubMed Central ID:: PMC9032366
DOI:: 10.1371/journal.pone.0267324
PMID:: 35452483
: Czasopismo naukowe

Pełny tekst

Introduction: Growth hormone (GH) deficiency (GHD) is often complicated by non-functioning pituitary tumors (NFPTs); however, its prevalence remains unclear because preoperative screening for GHD with provocative tests is not recommended. Accordingly, we attempted to clarify the characteristics of GHD in unoperated patients with NFPT.
Materials and Methods: We retrospectively reviewed adult patients with non-functioning pituitary adenoma (NFPA) and Rathke's cyst who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests from January 2013 to December 2016. We investigated the association between peak GH response to GHRP-2 and background characteristics.
Results: Among 104 patients (85 NFPA and 19 Rathke's cysts), 45 (43%) presented severe GHD, as diagnosed using GHRP-2 tests. Body mass index (β = -0.210, P = 0.007), free thyroxine (β = 0.440, P < 0.001), and tumor height (β = -0.254, P < 0.001) were significant variables for determining the peak GH response to GHRP-2 in multiple regression analyses. Overweight (odds ratio, 3.86; 95% confidence interval, 1.02-14.66) was significantly associated with severe GHD after adjustment for age, sex, creatinine, free thyroxine, tumor height and clinical diagnosis. The regression slopes between tumor height and peak GH response to GHRP-2 significantly differed between overweight patients and non-overweight individuals, as determined by analysis of covariance (P = 0.040). In the 48 patients who underwent postoperative GHRP-2 tests, severe postoperative GHD was significantly more common in overweight patients than non-overweight individuals (100% vs. 48%, P < 0.001).
Conclusion: We observed a negative synergistic effect between overweight and tumor size on GH secretion in patients with NFPTs, indicating that GH provocation tests for diagnosing underestimated GHD could be considered in overweight unoperated patients with large NFPTs.
Competing Interests: The authors have declared that no competing interests exist.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja